Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol
- Narmeen Mallah; Sonia Ares-Gómez; Jacobo Pardo-Seco; Alberto Malvar-Pintos; María-Isolina Santiago-Pérez; Olaia Pérez-Martínez
Access Resources
About
This article describes the NIRSE-GAL study in Galicia, Spain that aims to assess nirsevimab's effectiveness against RSV-related hospitalizations and other infections. Nirsevimab is licensed for universal RSV prevention in infants. Immunization campaigns target infants based on age and risk factors, lasting the whole season. Follow-up includes monitoring outcomes and estimating effectiveness using regression models. The study was approved by the ethics committee and will share findings through publications and conferences.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.